12 recruiting, 7 active not recruiting, 4 not yet recruiting, 3 completed. 28 Phase 3, 10 Phase 2.
Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| Blinatumomab for Treatment of Refractory Myasthenia Gravis Blinatumomab - Myasthenia Gravis | Phase 2 / Phase 3 | Not yet recruiting | Da, Yuwei, M.D. | 2 | 2025-04-01 | 2025-03-25 |
| Newly-diagnosed Pediatric Ph-positive B-ALL Protocol olverembatinib - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 150 | 2025-03-28 | 2025-09-03 |
| Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 3000 | 2025-03-03 | 2025-08-26 |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1800 | 2025-01-03 | 2026-07-23 |
| Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) Blinatumomab - Myasthaenia Gravis | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 10 | 2024-11-30 | 2024-11-12 |
| Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia Blinatumomab - B-Cell Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 90 | 2024-05-21 | 2024-09-23 |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia Blinatumomab - Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia | Phase 3 | Recruiting | Princess Maxima Center for Pediatric Oncology | 160 | 2022-12-15 | 2026-10-19 |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen - Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Active not recruiting | Amgen | 303 | 2021-11-02 | 2026-06-30 |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Ponatinib + Blinatumomab, Chemotherapy + Imatinib - Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult | Phase 3 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 236 | 2021-09-08 | 2025-01-23 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-11-12 |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy - Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Mats Heyman | 6430 | 2020-07-13 | 2026-08-12 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-12 |
Showing 20 of 28. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Burkitt Lymphoma (9) · Leukemia (4) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Leukemia, Biphenotypic, Acute (2) · Neoplasms (2) · Down Syndrome (1) · Graft vs Host Disease (1) · Immunoproliferative Disorders (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoproliferative Disorders (1) · Myasthenia Gravis (1)
Amgen (6) · Institute of Hematology & Blood Diseases Hospital, China (4) · National Cancer Institute (NCI) (4) · Assistance Publique - Hôpitaux de Paris (1) · Bambino Gesù Hospital and Research Institute (1) · Charite University, Berlin, Germany (1) · Children's Oncology Group (1) · Da, Yuwei, M.D. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Martin Schrappe (1) · Mats Heyman (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Princess Maxima Center for Pediatric Oncology (1) · Shanghai Jiao Tong University School of Medicine (1)
Australia (10) · Italy (10) · France (9) · Israel (9) · United States (9) · Canada (8) · Germany (8) · Spain (8) · Austria (7) · Belgium (7) · Czechia (7) · Denmark (7) · Netherlands (6) · Puerto Rico (6) · Sweden (6)
Xiaofan Zhu, MD (3) · Arend von Stackelberg, Dr. med., MD (1) · Franco Locatelli, Professor (1) · Hiroto Inaba, MD, PhD (1) · Janine Stutterheim, Dr (1) · Jennifer L McNeer (1) · Mark R Litzow (1) · Martin Schrappe, MD (1) · Mats Heyman, MD, PhD (1) · Patrick A Brown (1) · Sumit Gupta (1) · Yishai Ofran (1)
PMID 41671463, PMID 32289160, PMID 32546071, PMID 32589970, PMID 33542479, PMID 33651090, PMID 33844429, PMID 34161631, PMID 35129146, PMID 35501736, PMID 35622074, PMID 36000952, PMID 37141547, PMID 37257143, PMID 38841802, PMID 39047240, PMID 39214018, PMID 39651791, PMID 40568722, PMID 42154791, PMID 42748428, PMID 42832396, PMID 42874102
2025 (3), U10CA180886 (3), 2023 (2), U10CA180820 (2), 2014 (1), 2016 (1), U10CA021115 (1), U10CA098543 (1), U24CA196172 (1)